Annexon's neurological disease drug succeeds in late-stage study

Annexon (ANNX.O) said on Tuesday a late-stage study showed its experimental drug helped improve motor functions in patients with Guillain-Barre syndrome, a neurological disease in which the body's immune system attacks the nerves and can cause paralysis and even death.